Company intelligence / Profile preview

Incisive Technologies

Melbourne, Victoria, Australiaincisive-technologies.com ↗

Ownership: Private
Development stage: Commercial

Overview

Incisive Technologies has developed BlueCheck, a protein-based diagnostic liquid that visually identifies early-stage tooth decay by binding to porous enamel. The technology is highly sensitive and enables earlier intervention than traditional methods. BlueCheck received FDA 510k clearance in May 2023 and is being commercialized, with clinical collaborations ongoing to further validate its utility[1][4].

Therapeutic areas: Other
Modalities: DeviceProtein (as a diagnostic reagent component)
Industry: Protein Biomarker Diagnostics

Drug pipeline

1 asset

BlueCheck

Commercial

Indications: Dental caries detection

Partnerships

CareQuest Innovation Partners (Boston) – leading US dental advocacy group supporting commercialization and US entry[1]

Beyond the preview

Go deeper on Incisive Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Incisive Technologies.

Explore the full profile